Please login to the form below

Not currently logged in

Nycomed expands in China

Swiss pharma company Nycomed acquires majority stake in Guangdong Techpool Bio-Pharma

Nycomed is expanding its presence in China through the acquisition of a majority stake (51.34 per cent) in Guangdong Techpool Bio-Pharma Co (Techpool), a Chinese bio-pharmaceutical company.

Techpool, founded in 1993, specialises in the research, development, manufacturing and marketing of biologic drugs derived from natural sources. Its portfolio includes innovative protein drugs Ulinastatin, a broad-acting trypsin inhibitor, for the treatment of sepsis and multiple organ dysfunctions and Kallikrein, a serine protease, which is used in the treatment of stroke.

Techpool has a strong intellectual property position, including 35 patents filed, of which 17 have been granted, including one US patent approval.

Shanghai Pharmaceutical Group, a Chinese pharmaceutical conglomerate, holds 40.8 per cent of the shares of Techpool and was previously the majority shareholder.

Nycomed believes there is significant potential for continued strong growth of Techpool's key products through expanded hospital and reimbursement coverage in China. While Nycomed China and Techpool will be run as separate companies, value will be created through various alliances between them. The two companies will continue to expand in China, focusing on five core brands: Ulinastatin, Kallikrein, Pantoloc, Ebrantil and Actovegin.

Håkan Björklund, CEO of Nycomed, said: "Techpool's speciality franchise is highly complementary to Nycomed's development strategy and will become a cornerstone of our international expansion in emerging markets."

Techpool's management team, headed by the founder and CEO Dr Fu, will play a pivotal role in Nycomed's future expansion and the alliance has the support of Techpool's existing shareholders, including Shanghai Pharmaceutical Group.

Techpool has a marketing network spanning the whole of China and its products are distributed throughout Japan, South Korea, India and Pakistan, among other countries.

Nycomed has branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management, along with a range of OTC products.

2nd November 2010


Featured jobs

Subscribe to our email news alerts


Add my company

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...